Chemistry:Lucitanib

From HandWiki
Short description: Chemical compound
Lucitanib
Lucitanib.svg
Clinical data
Other namesCO-3810, E-3810
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life31–40 hrs
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC26H25N3O4
Molar mass443.503 g·mol−1
3D model (JSmol)

Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours[1] including metastatic breast cancer.[2] It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.[1]

References

  1. 1.0 1.1 "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology 25 (11): 2244–51. November 2014. doi:10.1093/annonc/mdu390. PMID 25193991. 
  2. Clinical trial number NCT02053636 for "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)" at ClinicalTrials.gov